Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-20.00/-0.41
|
|
Enterprise Value
3.28M
|
| Balance Sheet |
|
Book Value Per Share
24.28
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
0
|
|
Operating Revenue Per Share
1.08
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/15 19:31 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasivebladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers. |

5.48 
